Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04540107Phase 1Recruiting

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Role: lead

NCT03739411Phase 1Recruiting

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Role: lead

NCT04019002Phase 1Completed

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Role: lead

NCT00823459Phase 2Completed

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Role: lead

NCT03335280Terminated

68Ga-citrate PET/MR Imaging for Glioma

Role: lead

All 5 trials loaded